Q4/2019 12/31/2019 EPS -1.980 ZacksConsensus -2.250 ActVsEst 0.270 - Beat
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Biodefense Global Industry Overview 2021-2030: AI and Machine Learning to Revolutionize Early Detection and Response [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.MarketBeat
- ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/31/24 - Beat
ALNY
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 10/31/24 - Form 10-Q
- ALNY's page on the SEC website